2026-05-25T01:22:02Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/2455-1414.000081 2020-09-18 PTZ.JCRO:VOL7

Draw attention to the teratogenic effect of DMD in MS treatment Shi-Fang Hou Yin Jian Li-Yan Qiao Zun-Bao Li Kai FengXian-Hao Xu<p>More than 2.3 million people are affected by Multiple Sclerosis (MS) worldwide. Since the 1990s, disease modifying drug (DMD) has been developing increasingly. With more and more clinical applications, more and more attention has been paid to the adverse effects of DMD in the treatment of MS. DMD selection for patients with MS during pregnancy is one of the most important topics for neuroimmunologists and obstetrics. This comment is mainly based on our published and forthcoming data.&nbsp;</p><p><br></p> Journal of Clinical Research and Ophthalmology - Peertechz Publications 2020-09-18 Mini Review https://doi.org/10.17352/2455-1414.000081 en Copyright © Shi-Fang Hou et al.